Novo Nordisk starts new CagriSema weightloss drug trial
COPENHAGEN, June 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential after disappointing data from two previous studies.
The Danish company made the announcement in an entry published on www.clinicaltrials.gov., opens new tab
"This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term," Novo Nordisk said in the entry.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
2 hours ago
- Telegraph
Weight-loss drugs could become as common as statins, says England's top doctor
Weight-loss jabs could eventually be doled out like statins, England's top doctor has said. Prof Sir Stephen Powis, medical director of the NHS, said the health service should consider the mass rollout of medication to 'turn the tide' on Britain's obesity crisis. The NHS has been criticised for tightly rationing the jabs, having drawn up a plan for a 12-year rollout. GPs in England will start prescribing the injections from this month, but only to those with severe obesity and at least one weight-related health problem. Until now, jabs have only been available via specialist services with long waiting lists. However, NHS pilot schemes will look at ways to roll them out far more widely, including offering jabs through the post, from online pharmacies. Statins are one of the most commonly prescribed drugs in the UK, with about eight million people taking them to cut their chance of a heart attack and stroke. An estimated 1.5 million people are taking weight-loss jabs in the UK, with the vast majority paying for them privately, at around £200 a month. 'Exciting milestone' Speaking at the NHS ConfedExpo conference in Manchester, Sir Stephen hailed the rollout in GP surgeries as an 'exciting milestone' and said NHS officials are also examining ways to ' broaden access to the drugs '. Around 29 per cent of adults in the UK are obese. Sir Stephen said: 'Right now, obesity is estimated to cost the NHS approximately £11.4 billion every year – this financial burden is unsustainable for the NHS and wider economy. 'We have to turn the tide. We have to and will go further, and faster. 'In just a few years from now, some of today's weight-loss drugs will be available at much lower cost. This could completely transform access to these innovative treatments. 'But we will and must be guided by the evidence base and must do this safely and sustainably, in a way that ensures that we are equipped as a health service to deal with the demand.' 'We'll learn how to deploy them better' Sir Stephen said that the 'exciting new class of medication' would see wider rollout in the same way that statins had been rolled out en masse. 'There will be more drugs coming on the market. There will be different prices for drugs. We will get to generics, which means that prices will fall,' he said. 'We have been through this over statins, and the use of statins is now very different from when they first came out, and I've no doubt that will be the same for these drugs. So it's very exciting.' The senior doctor said research suggesting they can prevent and treat multiple diseases, including heart and kidney disease, also meant they were like statins. 'It's highly likely that they will become more widespread, the evidence base will increase. We will learn better how to deploy them,' he said.
Daily Mail
5 hours ago
- Daily Mail
Achieve a HEALTHY summer body with the personal coaching app that helps you shed weight for good - see the before and after photo proof here
Losing weight takes some serious effort. The reality is that it's a struggle for many, whether they have issues with motivation or moderation. Wouldn't it be amazing to have someone who was constantly by your side to cheer you on? With the Simple app, you quite literally always have a personal weight loss cheerleader in your pocket. The streamlined platform is designed to simplify the way you approach your goals, tailoring a plan that takes into account your personal challenges while helping you learn healthier habits over time. Simple It's time to take control of your weight loss goals! Simple is an app that helps you achieve them without the usual struggles. It's like having a motivating personal coach in your pocket! The AI-powered platform is a joy to use, helping you make the right dietary choices, keep track of your goals, monitor your progress, and more. You can contact your virtual coach 24/7 for real-time responses whenever you need them. The before and after photographs speak for themselves — Simple really works! Get Started Beautiful results: Users like Danielle have shared their incredible before and after photos revealing impressive weight loss thanks to the Simple app That's often the key to seeing results that last. When you change the way you eat, everything changes for the better. Through Simple's AI-powered coaching, you'll discover how to make the best choices while understanding the 'whys' behind them. Because that's important, too — and it's critical to making behavioral changes that have a chance of sticking so you can be healthy both now and in the future. You'll never feel guilted out of enjoying something you love, either. 'Everything in moderation' has always been an important adage, and it applies here, too. Instead, Simple focuses on helping you achieve a more balanced lifestyle. No more restricting entire food groups you love or obsessively counting calories. Those are old, played out behaviors that are intrinsically more harmful than helpful. What sets this app apart is that it genuinely prioritizes your wellbeing. Chat with your coach at any time and you'll receive straightforward, friendly, non-judgmental guidance during your journey. You'll only ever feel uplifted and motivated! And it's backed by science, which is equally vital to your success. The entire goal is to help you lose the weight you want to lose and keep it off, which is why Simple encourages you to make small changes every day that gradually become a part of your everyday routine. That is what makes long-term success possible. It's fun, too! Your onboarding process begins with a detailed questionnaire in which you'll provide information about your weight loss journey, current diet, and goals. It even provides you with a prediction of when you might expect to see results. Habits for life: Simple is designed to simplify the often complicated world of weight loss, helping you make healthier choices that work Plus, it's jam-packed with useful features — like NutriScanner, which gives you insight into nutrition from your favorite restaurant menus, intermittent fasting monitoring, nutrition scores for your meals, and a wealth of educational content. You can also pair the app with your smartwatch for seamless on-the-go coaching. The results are absolutely astounding, with Simple users sharing dramatic photo evidence of their success. One couple lost an impressive 117 pounds together, and countless users have shed dramatic weight in as little as four weeks. Why wait? If you're ready to achieve a truly healthy summer body that turns into the lifelong body of your dreams, get started with the Simple app today.
Reuters
5 hours ago
- Reuters
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year
June 12 (Reuters) - Novo Nordisk ( opens new tab said on Thursday it plans to start late-stage trials of its experimental weight-loss drug amycretin in injection and oral forms during the first quarter of 2026 for adults who are overweight or obese. The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said. Amycretin, the Danish drugmaker's next generation obesity drug, has a dual mode action. Like its popular weight-loss drug Wegovy, amycretin mimics the gut hormone GLP-1, but it also mimics the effect of a hunger-suppressing pancreatic hormone called amylin.
